首页 > 最新文献

Journal of Research in Pharmacy Practice最新文献

英文 中文
Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence. 2019 年冠状病毒疾病的药理和非药理研究:最新证据小综述》。
IF 0.8 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_71
Amir Hossein Alizadeh Bahmani, Mehdi Hoorang, Sheida Hosseini, Mehrnoosh Eskandari, Kiana Shayestehfard, Mahyar Shekoohi, Nazafarin Hatami-Mazinani, Saba Afifi, Ali Mohammad Sabzghabaee, Payam Peymani

Coronavirus 19 (COVID-19) is an extremely transmittable microbial infection that has emerged in Wuhan (China) in late 2019, leading to severe acute respiratory syndrome coronavirus 2 syndrome, and caused a pandemic all over the globe. This study is a systematic review of all 927 clinical trial studies performed worldwide from the beginning of the COVID-19 mysterious pandemic in China. These researches have registered in different databases. According to the best of our knowledge, China (74.82%), the United States (4.49%), and France (2.72%) have the most significant number of clinical trials, respectively. Clinical trials can be randomized or nonrandomized. Due to our results, 32.58% of studies were randomized, and 7.12% were not randomized. Most of the studies were open-labeled studies (22.44%), and double-blinded (4.42%) and quadruple blinded (2.48%) studies stand in second and third place regarding the number of trials, respectively. The direction and quantity of clinical trials attempted to identify a possible cure for COVID-19 demonstrates the depth of this crisis. As we are writing this article, a significant international endeavor will find a cure or vaccine for containing this devastating and mysterious disease.

冠状病毒19(COVID-19)是一种极易传播的微生物感染,2019年底在中国武汉出现,导致严重急性呼吸道综合征冠状病毒2综合征,并在全球引起大流行。本研究系统回顾了自中国 COVID-19 神秘大流行开始以来全球进行的所有 927 项临床试验研究。这些研究已在不同的数据库中登记。据我们所知,中国(74.82%)、美国(4.49%)和法国(2.72%)分别拥有最多的临床试验。临床试验可以是随机的,也可以是非随机的。根据我们的研究结果,32.58%的研究为随机研究,7.12%的研究为非随机研究。大部分研究为开放标签研究(22.44%),双盲研究(4.42%)和四重盲研究(2.48%)的数量分别排在第二和第三位。为寻找治疗 COVID-19 的可能方法而进行的临床试验的方向和数量表明了这场危机的严重性。就在我们撰写这篇文章的时候,国际上正在努力寻找治疗这种毁灭性神秘疾病的方法或疫苗。
{"title":"Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence.","authors":"Amir Hossein Alizadeh Bahmani, Mehdi Hoorang, Sheida Hosseini, Mehrnoosh Eskandari, Kiana Shayestehfard, Mahyar Shekoohi, Nazafarin Hatami-Mazinani, Saba Afifi, Ali Mohammad Sabzghabaee, Payam Peymani","doi":"10.4103/jrpp.JRPP_20_71","DOIUrl":"10.4103/jrpp.JRPP_20_71","url":null,"abstract":"<p><p>Coronavirus 19 (COVID-19) is an extremely transmittable microbial infection that has emerged in Wuhan (China) in late 2019, leading to severe acute respiratory syndrome coronavirus 2 syndrome, and caused a pandemic all over the globe. This study is a systematic review of all 927 clinical trial studies performed worldwide from the beginning of the COVID-19 mysterious pandemic in China. These researches have registered in different databases. According to the best of our knowledge, China (74.82%), the United States (4.49%), and France (2.72%) have the most significant number of clinical trials, respectively. Clinical trials can be randomized or nonrandomized. Due to our results, 32.58% of studies were randomized, and 7.12% were not randomized. Most of the studies were open-labeled studies (22.44%), and double-blinded (4.42%) and quadruple blinded (2.48%) studies stand in second and third place regarding the number of trials, respectively. The direction and quantity of clinical trials attempted to identify a possible cure for COVID-19 demonstrates the depth of this crisis. As we are writing this article, a significant international endeavor will find a cure or vaccine for containing this devastating and mysterious disease.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"175-180"},"PeriodicalIF":0.8,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/ca/JRPP-9-175.PMC8067895.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitivity and Specificity of prior Methicillin-Resistant Staphylococcus aureus Nasal Swab Results for Predicting Methicillin-Resistant Staphylococcus aureus Infections in Intensive Care Unit Admissions Over a 1-Year Period: A Pilot Study. 既往耐甲氧西林金黄色葡萄球菌鼻拭子结果预测1年重症监护病房住院患者耐甲氧西林金黄色葡萄球菌感染的敏感性和特异性:一项试点研究
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_86
Jonathan Wadle, Geoffrey C Wall, Hayden S Smith

Objective: Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a pathogen worldwide. Empiric anti-MRSA therapy is often prescribed in hospital inpatients with potential infection. Recent studies have suggested, particularly for respiratory infections, that MRSA colonization as determined by nasal swab has a high negative predictive value (NPV) for MRSA infections during the index hospitalization. We examined the predictive value of a prior intensive care unit (ICU) MRSA nasal swab on the results from a subsequent ICU admission in the same patient and the results of the latter admission MRSA nasal swab.

Methods: A retrospective chart review of patients 18 years or older admitted to a large tertiary care hospital in the Midwest of the United States in 2016 who had a MRSA nasal swab performed and had an ICU admission stay of over 24 h was conducted. This group of patients was matched to a patient list of subjects who were admitted as an inpatient to the same ICU at least once during the following year. Data were collected on demographic and clinical information, as well as the results of MRSA swabs and the presence of a MRSA infection during both hospitalizations. Predictive values were calculated using 2 × 2 tables including sensitivity and specificity of a first MRSA swab result with a MRSA infection during the subsequent ICU stay.

Findings: Seventy-seven patients were matched who had MRSA swabs performed on two separate ICU admissions. The negative predictive value of the first MRSA swab result on a MRSA infection during the second ICU stay was 96%.

Conclusion: In this pilot study, a previous negative MRSA nasal swab may predict a lack of a MRSA infection in a subsequent infection during a 1-year period.

目的:耐甲氧西林金黄色葡萄球菌(MRSA)仍然是世界范围内的一种病原体。经验性抗mrsa治疗通常用于潜在感染的住院患者。最近的研究表明,特别是呼吸道感染,通过鼻拭子确定的MRSA定植对住院期间MRSA感染具有很高的阴性预测值(NPV)。我们研究了重症监护室(ICU)前一次MRSA鼻拭子对同一患者随后ICU入院结果和后一次入院MRSA鼻拭子结果的预测价值。方法:回顾性分析2016年美国中西部某大型三级医院收治的18岁及以上、行MRSA鼻拭子检查且ICU住院时间超过24 h的患者。这组患者与一组患者名单相匹配,这些患者在接下来的一年中作为住院患者至少入住同一ICU一次。收集了人口统计学和临床信息,以及MRSA拭子结果和两次住院期间是否存在MRSA感染的数据。使用2 × 2表计算预测值,包括首次MRSA拭子结果与随后ICU住院期间MRSA感染的敏感性和特异性。结果:77例患者在两次单独的ICU住院期间接受了MRSA拭子检查。第一次MRSA拭子结果对第二次ICU住院期间MRSA感染的阴性预测值为96%。结论:在这项初步研究中,先前的MRSA阴性鼻拭子可以预测1年内后续感染中没有MRSA感染。
{"title":"Sensitivity and Specificity of prior Methicillin-Resistant <i>Staphylococcus aureus</i> Nasal Swab Results for Predicting Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Intensive Care Unit Admissions Over a 1-Year Period: A Pilot Study.","authors":"Jonathan Wadle,&nbsp;Geoffrey C Wall,&nbsp;Hayden S Smith","doi":"10.4103/jrpp.JRPP_20_86","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_86","url":null,"abstract":"<p><strong>Objective: </strong>Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) continues to be a pathogen worldwide. Empiric anti-MRSA therapy is often prescribed in hospital inpatients with potential infection. Recent studies have suggested, particularly for respiratory infections, that MRSA colonization as determined by nasal swab has a high negative predictive value (NPV) for MRSA infections during the index hospitalization. We examined the predictive value of a prior intensive care unit (ICU) MRSA nasal swab on the results from a subsequent ICU admission in the same patient and the results of the latter admission MRSA nasal swab.</p><p><strong>Methods: </strong>A retrospective chart review of patients 18 years or older admitted to a large tertiary care hospital in the Midwest of the United States in 2016 who had a MRSA nasal swab performed and had an ICU admission stay of over 24 h was conducted. This group of patients was matched to a patient list of subjects who were admitted as an inpatient to the same ICU at least once during the following year. Data were collected on demographic and clinical information, as well as the results of MRSA swabs and the presence of a MRSA infection during both hospitalizations. Predictive values were calculated using 2 × 2 tables including sensitivity and specificity of a first MRSA swab result with a MRSA infection during the subsequent ICU stay.</p><p><strong>Findings: </strong>Seventy-seven patients were matched who had MRSA swabs performed on two separate ICU admissions. The negative predictive value of the first MRSA swab result on a MRSA infection during the second ICU stay was 96%.</p><p><strong>Conclusion: </strong>In this pilot study, a previous negative MRSA nasal swab may predict a lack of a MRSA infection in a subsequent infection during a 1-year period.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"208-211"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/57/JRPP-9-208.PMC8067898.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Pharmacist Intervention on Medication Adherence and Clinical Outcomes of Type 2 Diabetes Mellitus Outpatients in Primary Healthcare in Indonesia. 药师干预对印尼初级卫生保健门诊2型糖尿病患者服药依从性和临床结局的影响
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_59
Nani Apriani Besemah, Ratu Ayu Dewi Sartika, Rani Sauriasari

Objective: In Indonesia, the role of pharmacists in primary healthcare is still very limited or even absent. This study evaluates the effectiveness of programs delivered for type 2 diabetes mellitus (T2DM) patients by pharmacists in primary healthcare through counseling, short message service (SMS) reminders, and medication booklets.

Methods: A quasi-experimental study with a pretest-posttest design was conducted from April to August 2018 at Merdeka and Dempo primary health-care centers, Palembang, South Sumatra Province, Indonesia. Counseling and medication booklets were distributed three times during the study period, while SMS reminders were sent once a week. Counseling was given for the management of diabetes mellitus (DM), including during the Ramadan fasting period, together with management for acute and chronic complications. The medication adherence level was measured using a medication adherence questionnaire (MAQ) and pill count adherence (PCA). The study sample comprised 80 T2DM patients, who were allocated into either the control group (CG) (n = 40) or intervention group (IG) (n = 40). Clinical outcomes were determined by measuring glycated hemoglobin (HbA1c), blood pressure, and lipid profiles.

Findings: After the intervention, the IG showed significant improvements in most parameters, except for high-density lipoprotein cholesterol and systolic and diastolic blood pressure. HbA1c levels were reduced, while MAQ scores and PCA scores were improved. Lipid parameters were significantly reduced total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and triglyceride (TG). Compared with the CG, most parameters were significantly improved in the IG. Pharmacist counseling significantly improved almost all clinical parameters (HbA1c, TC, LDL-c, and TG). Pharmacist counseling was 7.1 times greater in lowering HbA1c compared with no counseling, after adjusted by other variables. The variable that most influenced the lowering of HbA1c was infrequent ("not often") consumption of unhealthy foods (OR 14.9; 95% CI 3.5-63.7).

Conclusion: The pharmacist primary health-care intervention program implemented in this study significantly improved HbA1c, TC, LDL-c, TG, and medication adherence in outpatients with T2DM.

目的:在印度尼西亚,药剂师在初级卫生保健中的作用仍然非常有限,甚至不存在。本研究评估了药师在初级卫生保健中通过咨询、短信提醒和药物手册为2型糖尿病(T2DM)患者提供的方案的有效性。方法:2018年4 - 8月在印度尼西亚南苏门答腊省巨港市默迪卡和登波初级卫生保健中心采用前测后测设计进行准实验研究。研究期间发放了三次咨询和用药手册,并每周发送一次短信提醒。为管理糖尿病(DM)提供咨询,包括在斋月禁食期间,以及急性和慢性并发症的管理。采用药物依从性问卷(MAQ)和药丸数依从性(PCA)测量药物依从性水平。研究样本包括80例T2DM患者,分为对照组(CG) (n = 40)和干预组(IG) (n = 40)。通过测量糖化血红蛋白(HbA1c)、血压和血脂来确定临床结果。结果:干预后,IG除高密度脂蛋白胆固醇、收缩压和舒张压外,大多数参数均有显著改善。HbA1c水平降低,MAQ评分和PCA评分提高。脂质参数显著降低总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-c)和甘油三酯(TG)。与CG相比,IG组大部分参数均有明显改善。药师咨询可显著改善几乎所有临床参数(HbA1c、TC、LDL-c、TG)。经其他变量调整后,药师咨询降低HbA1c的效果是无药师咨询的7.1倍。对HbA1c降低影响最大的变量是不经常(“不经常”)食用不健康食品(OR 14.9;95% ci 3.5-63.7)。结论:本研究实施的药师初级卫生保健干预方案显著改善了门诊T2DM患者的HbA1c、TC、LDL-c、TG和药物依从性。
{"title":"Effect of Pharmacist Intervention on Medication Adherence and Clinical Outcomes of Type 2 Diabetes Mellitus Outpatients in Primary Healthcare in Indonesia.","authors":"Nani Apriani Besemah, Ratu Ayu Dewi Sartika, Rani Sauriasari","doi":"10.4103/jrpp.JRPP_20_59","DOIUrl":"10.4103/jrpp.JRPP_20_59","url":null,"abstract":"<p><strong>Objective: </strong>In Indonesia, the role of pharmacists in primary healthcare is still very limited or even absent. This study evaluates the effectiveness of programs delivered for type 2 diabetes mellitus (T2DM) patients by pharmacists in primary healthcare through counseling, short message service (SMS) reminders, and medication booklets.</p><p><strong>Methods: </strong>A quasi-experimental study with a pretest-posttest design was conducted from April to August 2018 at Merdeka and Dempo primary health-care centers, Palembang, South Sumatra Province, Indonesia. Counseling and medication booklets were distributed three times during the study period, while SMS reminders were sent once a week. Counseling was given for the management of diabetes mellitus (DM), including during the Ramadan fasting period, together with management for acute and chronic complications. The medication adherence level was measured using a medication adherence questionnaire (MAQ) and pill count adherence (PCA). The study sample comprised 80 T2DM patients, who were allocated into either the control group (CG) (<i>n</i> = 40) or intervention group (IG) (<i>n</i> = 40). Clinical outcomes were determined by measuring glycated hemoglobin (HbA1c), blood pressure, and lipid profiles.</p><p><strong>Findings: </strong>After the intervention, the IG showed significant improvements in most parameters, except for high-density lipoprotein cholesterol and systolic and diastolic blood pressure. HbA1c levels were reduced, while MAQ scores and PCA scores were improved. Lipid parameters were significantly reduced total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and triglyceride (TG). Compared with the CG, most parameters were significantly improved in the IG. Pharmacist counseling significantly improved almost all clinical parameters (HbA1c, TC, LDL-c, and TG). Pharmacist counseling was 7.1 times greater in lowering HbA1c compared with no counseling, after adjusted by other variables. The variable that most influenced the lowering of HbA1c was infrequent (\"not often\") consumption of unhealthy foods (OR 14.9; 95% CI 3.5-63.7).</p><p><strong>Conclusion: </strong>The pharmacist primary health-care intervention program implemented in this study significantly improved HbA1c, TC, LDL-c, TG, and medication adherence in outpatients with T2DM.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"186-195"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/e6/JRPP-9-186.PMC8067894.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment. 某三级医疗保健中心老年人处方药物与新冠肺炎治疗研究药物可能相互作用的评价
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_107
Yogendra Keche, Nitin Gaikwad, Suryaprakash Dhaneria, Apoorva Joshi

Objective: Earlier identifying drug interactions may help in risk reduction in elderly patients.

Methods: Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug interaction had been checked from Stockley's Drug Interaction 2019 and Martindale the Complete Drug Reference 2017 and standard reference books of Pharmacology.

Findings: Different types of drugs prescribed in the elderly were 260 and out of which 68 (26.36%) were in the category of fixed-dose combinations. Around 150 (70.75%) elderly patients were having one or more associated comorbidities. Thirty-five drugs prescribed to elderly had been found to cause drug interaction with investigational drugs for COVID-19. Possible drug interactions are mediated through CYP3A4 (eighteen patients), CYP2D6 (seven patients) isoenzymes, or P glycoproteins transporters (three patients).

Conclusion: Possible drug interactions predicted in this study suggested need for modification of dose of drug or watchfulness for adverse effects. If these drug interactions are considered beforehand, complications can be prevented on account of these drug interactions in elderly who are suffering from COVID-19.

目的:早期识别药物相互作用可能有助于降低老年患者的风险。方法:分析三级卫生保健中心212例老年患者的药物处方资料,分析其与治疗新冠肺炎的研究药物可能存在的药物相互作用。药物相互作用已从Stockley的《药物相互作用2019》和Martindale的《药物完全参考2017》和药理学标准参考书中进行了检查。结果:老年人处方不同类型药物260种,其中固定剂量联合用药68种,占26.36%;约150例(70.75%)老年患者有一种或多种相关合并症。已发现35种老年人处方药物与新冠肺炎研究药物相互作用。可能的药物相互作用是通过CYP3A4(18例)、CYP2D6(7例)同工酶或P糖蛋白转运蛋白(3例)介导的。结论:本研究预测可能的药物相互作用提示需要调整药物剂量或注意不良反应。如果事先考虑到这些药物相互作用,则可预防感染COVID-19的老年人因这些药物相互作用而出现并发症。
{"title":"Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.","authors":"Yogendra Keche,&nbsp;Nitin Gaikwad,&nbsp;Suryaprakash Dhaneria,&nbsp;Apoorva Joshi","doi":"10.4103/jrpp.JRPP_20_107","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_107","url":null,"abstract":"<p><strong>Objective: </strong>Earlier identifying drug interactions may help in risk reduction in elderly patients.</p><p><strong>Methods: </strong>Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug interaction had been checked from Stockley's Drug Interaction 2019 and Martindale the Complete Drug Reference 2017 and standard reference books of Pharmacology.</p><p><strong>Findings: </strong>Different types of drugs prescribed in the elderly were 260 and out of which 68 (26.36%) were in the category of fixed-dose combinations. Around 150 (70.75%) elderly patients were having one or more associated comorbidities. Thirty-five drugs prescribed to elderly had been found to cause drug interaction with investigational drugs for COVID-19. Possible drug interactions are mediated through CYP3A4 (eighteen patients), CYP2D6 (seven patients) isoenzymes, or <i>P</i> glycoproteins transporters (three patients).</p><p><strong>Conclusion: </strong>Possible drug interactions predicted in this study suggested need for modification of dose of drug or watchfulness for adverse effects. If these drug interactions are considered beforehand, complications can be prevented on account of these drug interactions in elderly who are suffering from COVID-19.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"212-217"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/23/JRPP-9-212.PMC8067896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38839399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines Availability among Hypertensive Patients in Primary Health Care Facilities in a Rural Province in South Africa: Findings and Implications. 南非一个农村省初级卫生保健机构中高血压患者的药物可得性:研究结果和意义
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_49
Enos M Rampamba, Johanna C Meyer, Elvera Helberg, Brian Godman

Objective: Controlling blood pressure (BP) in hypertensive patients is a challenge, with the lack of antihypertensive medicines negatively impacting on BP control. Consequently, we assessed the availability of prescribed antihypertensives among patients with chronic hypertension attending primary health care (PHC) facilities in a rural province of South Africa and explored any association between medicines availability, the number of prescribed antihypertensive medicines and BP control.

Methods: Secondary data that included patients' demographics, BP, and data on medicines availability of the intervention group from a 3 months' operational study conducted in rural PHC facilities in South Africa were analyzed. The association between medicines availability, the number of antihypertensive medicines, and BP control was explored.

Findings: Fifty-five African patients (89.1% females) with a mean age of 61.3 years were included. Two-thirds (67.2%) received all their medicines during their monthly visits, 25.5% received some, and for 7.3%, there was no record of whether medicines were dispensed or not. Patients with controlled BP (60.0%) were more likely to have been prescribed only one antihypertensive medicine compared to patients with uncontrolled BP (20.7%) (P = 0.017; odds ratio: 5.75; 95% confidence interval: 1.46, 22.61).

Conclusion: It is concerning that one-third of patients went home without all of their antihypertensive medicines from PHC facilities in this Province of South Africa where there is evidence of use of herbal medicines and uncontrolled BP contributing to high morbidity and mortality from cardiovascular diseases. Additional studies are needed to fully explore the association between medicines availability, their use, and BP control among patients.

目的:控制高血压患者的血压是一个挑战,缺乏降压药会对血压控制产生负面影响。因此,我们评估了南非一个农村省份初级卫生保健(PHC)机构的慢性高血压患者处方抗高血压药物的可获得性,并探讨了药物可获得性、处方抗高血压药物数量和血压控制之间的关系。方法:从南非农村初级保健机构进行的为期3个月的业务研究中,分析了包括患者人口统计学、血压和干预组药物可用性数据在内的次要数据。探讨药物可及性、降压药数量与血压控制之间的关系。结果:55例非洲患者(89.1%为女性),平均年龄61.3岁。三分之二(67.2%)的人在每月就诊时获得了全部药品,25.5%的人获得了部分药品,7.3%的人没有是否配药的记录。血压控制的患者(60.0%)比血压不控制的患者(20.7%)更有可能只开过一种降压药(P = 0.017;优势比:5.75;95%置信区间:1.46,22.61)。结论:令人担忧的是,在南非的这个省,有三分之一的患者回家时没有服用所有的抗高血压药物,有证据表明使用草药和不受控制的血压导致心血管疾病的高发病率和死亡率。需要进一步的研究来充分探索药物的可获得性、使用和患者血压控制之间的关系。
{"title":"Medicines Availability among Hypertensive Patients in Primary Health Care Facilities in a Rural Province in South Africa: Findings and Implications.","authors":"Enos M Rampamba,&nbsp;Johanna C Meyer,&nbsp;Elvera Helberg,&nbsp;Brian Godman","doi":"10.4103/jrpp.JRPP_20_49","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_49","url":null,"abstract":"<p><strong>Objective: </strong>Controlling blood pressure (BP) in hypertensive patients is a challenge, with the lack of antihypertensive medicines negatively impacting on BP control. Consequently, we assessed the availability of prescribed antihypertensives among patients with chronic hypertension attending primary health care (PHC) facilities in a rural province of South Africa and explored any association between medicines availability, the number of prescribed antihypertensive medicines and BP control.</p><p><strong>Methods: </strong>Secondary data that included patients' demographics, BP, and data on medicines availability of the intervention group from a 3 months' operational study conducted in rural PHC facilities in South Africa were analyzed. The association between medicines availability, the number of antihypertensive medicines, and BP control was explored.</p><p><strong>Findings: </strong>Fifty-five African patients (89.1% females) with a mean age of 61.3 years were included. Two-thirds (67.2%) received all their medicines during their monthly visits, 25.5% received some, and for 7.3%, there was no record of whether medicines were dispensed or not. Patients with controlled BP (60.0%) were more likely to have been prescribed only one antihypertensive medicine compared to patients with uncontrolled BP (20.7%) (<i>P</i> = 0.017; odds ratio: 5.75; 95% confidence interval: 1.46, 22.61).</p><p><strong>Conclusion: </strong>It is concerning that one-third of patients went home without all of their antihypertensive medicines from PHC facilities in this Province of South Africa where there is evidence of use of herbal medicines and uncontrolled BP contributing to high morbidity and mortality from cardiovascular diseases. Additional studies are needed to fully explore the association between medicines availability, their use, and BP control among patients.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"181-185"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/6c/JRPP-9-181.PMC8067899.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia. 高血压患者的药物相关问题:印度尼西亚横断面研究》。
IF 0.8 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2020-10-08 eCollection Date: 2020-07-01 DOI: 10.4103/jrpp.JRPP_20_16
Larasati Arrum Kusumawardani, Retnosari Andrajati, Azizah Nusaibah

Objective: The treatment of hypertension requires special attention because of comorbidities and polypharmacy. In a previous study, polypharmacy has been associated with a high risk of drug-related problems (DRPs). This study aimed to analyze DRPs in Indonesian hypertensive patients focusing on drug therapy effectiveness and adverse drug reactions.

Methods: A cross-sectional study was conducted using medical records' data, prescriptions, and nursing records to observe DRPs that occurred in outpatients with hypertension from February to April 2019. A total of 114 outpatients aged ≥23 years with a primary diagnosis of primary hypertension were included in this study. DRPs were reviewed based on literature, recent guidelines, and drug interaction software. Classification DRPs were done using Indonesian-translated Pharmaceutical Care Network Europe V6.02. The data obtained were analyzed using univariate descriptive analysis.

Findings: Of all participants, 65 (57%) outpatients were found to have DRPs related to treatment effectiveness (54 cases) and adverse drug reactions (36 cases). The primary cause of the problems was an inappropriate drug (94.14%) and dose selection (2.86%). Potential drug interactions were found high (62.14%) in the combination of an antihypertensive agent with other drugs among patients. Overprescribing drugs without clear indications, untreated indications, and subtherapeutic dosage were also reported in this study.

Conclusion: A significant percentage of outpatients being treated for hypertension experienced DRPs. The role of clinical pharmacists and physicians in monitoring drug therapy needs to be prioritized to prevent and resolve DRPs in outpatients with hypertension.

目的:由于合并症和多重用药,高血压的治疗需要特别注意。在之前的一项研究中,多重用药与药物相关问题(DRPs)的高风险有关。本研究旨在分析印尼高血压患者的药物相关问题,重点关注药物治疗效果和药物不良反应:采用病历数据、处方和护理记录进行横断面研究,观察2019年2月至4月期间高血压门诊患者发生的DRP。本研究共纳入了 114 名年龄≥23 岁、主要诊断为原发性高血压的门诊患者。根据文献、最新指南和药物相互作用软件对DRP进行了审查。使用印尼语翻译的Pharmaceutical Care Network Europe V6.02对DRP进行分类。所得数据采用单变量描述性分析法进行分析:在所有参与者中,有 65 名(57%)门诊患者被发现患有与治疗效果(54 例)和药物不良反应(36 例)有关的 DRP。出现问题的主要原因是用药不当(94.14%)和剂量选择不当(2.86%)。发现患者在联合使用一种降压药和其他药物时,潜在的药物相互作用较高(62.14%)。本研究还报告了在没有明确适应症的情况下超量处方药物、未治疗的适应症和治疗剂量不足的情况:结论:在接受高血压治疗的门诊病人中,有相当大比例的人曾经历过药物滥用。临床药剂师和医生在监测药物治疗方面的作用需要优先考虑,以预防和解决门诊高血压患者的药物滥用问题。
{"title":"Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia.","authors":"Larasati Arrum Kusumawardani, Retnosari Andrajati, Azizah Nusaibah","doi":"10.4103/jrpp.JRPP_20_16","DOIUrl":"10.4103/jrpp.JRPP_20_16","url":null,"abstract":"<p><strong>Objective: </strong>The treatment of hypertension requires special attention because of comorbidities and polypharmacy. In a previous study, polypharmacy has been associated with a high risk of drug-related problems (DRPs). This study aimed to analyze DRPs in Indonesian hypertensive patients focusing on drug therapy effectiveness and adverse drug reactions.</p><p><strong>Methods: </strong>A cross-sectional study was conducted using medical records' data, prescriptions, and nursing records to observe DRPs that occurred in outpatients with hypertension from February to April 2019. A total of 114 outpatients aged ≥23 years with a primary diagnosis of primary hypertension were included in this study. DRPs were reviewed based on literature, recent guidelines, and drug interaction software. Classification DRPs were done using Indonesian-translated Pharmaceutical Care Network Europe V6.02. The data obtained were analyzed using univariate descriptive analysis.</p><p><strong>Findings: </strong>Of all participants, 65 (57%) outpatients were found to have DRPs related to treatment effectiveness (54 cases) and adverse drug reactions (36 cases). The primary cause of the problems was an inappropriate drug (94.14%) and dose selection (2.86%). Potential drug interactions were found high (62.14%) in the combination of an antihypertensive agent with other drugs among patients. Overprescribing drugs without clear indications, untreated indications, and subtherapeutic dosage were also reported in this study.</p><p><strong>Conclusion: </strong>A significant percentage of outpatients being treated for hypertension experienced DRPs. The role of clinical pharmacists and physicians in monitoring drug therapy needs to be prioritized to prevent and resolve DRPs in outpatients with hypertension.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 3","pages":"140-145"},"PeriodicalIF":0.8,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/d4/JRPP-9-140.PMC7808178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38776454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serotonin Toxicity Following Suicide with Citalopram and Lamotrigine: A Rare Case Report and Literature Review. 西酞普兰和拉莫三嗪自杀后血清素毒性:一例罕见病例报告和文献回顾。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2020-10-08 eCollection Date: 2020-07-01 DOI: 10.4103/jrpp.JRPP_19_105
Gholamali Dorooshi, Shafeajafar Zoofaghari, Rokhsareh Meamar

Serotonin toxicity is a common but often unrecognized toxicological condition. In most cases, a combination of two or more serotonergic drugs can cause serotonin syndrome. We describe a case of serotonin toxicity in a 17-year-old woman, secondary to suicidal ingestion of 1000 mg lamotrigine and 400 mg citalopram, which has been rarely reported. Our patient had a medical history of depression and was treated with lamotrigine and citalopram. She was brought to the emergency room with nausea, diaphoresis, agitation, shivering, tremor, vertigo, ataxia, mydriasis, nystagmus, hyperreflexia, myoclonus, tachycardia, tachypnea, and mild fever. The symptoms and signs were resolved within 3 days following hydration, sedation, and cyproheptadine. Minor cardiovascular symptoms are probably due to the less toxic dose of citalopram. Lamotrigine, especially in combination with other serotonergic drugs, should be considered a cause of serotonin toxicity.

血清素毒性是一种常见但通常未被认识到的毒理学状况。在大多数情况下,两种或两种以上的血清素能药物联合使用可引起血清素综合征。我们描述了一例17岁女性血清素毒性,继发于自杀性摄入1000毫克拉莫三嗪和400毫克西酞普兰,这很少有报道。我们的病人有抑郁症病史,并接受拉莫三嗪和西酞普兰的治疗。她因恶心、出汗、躁动、颤抖、震颤、眩晕、共济失调、泪液散失、眼球震颤、反射亢进、肌阵挛、心动过速、呼吸急促和轻度发烧被送到急诊室。在补液、镇静和使用赛庚啶后3天内症状和体征消失。轻微的心血管症状可能是由于西酞普兰的毒性剂量较小。拉莫三嗪,特别是与其他血清素能药物联合使用时,应被认为是血清素毒性的一个原因。
{"title":"Serotonin Toxicity Following Suicide with Citalopram and Lamotrigine: A Rare Case Report and Literature Review.","authors":"Gholamali Dorooshi,&nbsp;Shafeajafar Zoofaghari,&nbsp;Rokhsareh Meamar","doi":"10.4103/jrpp.JRPP_19_105","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_19_105","url":null,"abstract":"<p><p>Serotonin toxicity is a common but often unrecognized toxicological condition. In most cases, a combination of two or more serotonergic drugs can cause serotonin syndrome. We describe a case of serotonin toxicity in a 17-year-old woman, secondary to suicidal ingestion of 1000 mg lamotrigine and 400 mg citalopram, which has been rarely reported. Our patient had a medical history of depression and was treated with lamotrigine and citalopram. She was brought to the emergency room with nausea, diaphoresis, agitation, shivering, tremor, vertigo, ataxia, mydriasis, nystagmus, hyperreflexia, myoclonus, tachycardia, tachypnea, and mild fever. The symptoms and signs were resolved within 3 days following hydration, sedation, and cyproheptadine. Minor cardiovascular symptoms are probably due to the less toxic dose of citalopram. Lamotrigine, especially in combination with other serotonergic drugs, should be considered a cause of serotonin toxicity.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 3","pages":"158-160"},"PeriodicalIF":1.0,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/78/JRPP-9-158.PMC7808175.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38789577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Increased Risk of Arrhythmia in COVID-19 Patients: Possible Roles of Both the Disease Pathophysiology and Adverse Drug Reactions. COVID-19患者心律失常风险增加:疾病病理生理和药物不良反应的可能作用
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2020-10-08 eCollection Date: 2020-07-01 DOI: 10.4103/jrpp.JRPP_20_63
Ali Rismanbaf
References 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Discovery of a Novel Coronavirus Associated with the Recent Pneumonia Outbreak in Humans and its Potential Bat Origin. BioRxiv; 2020. 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9. 3. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60. 4. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: Mind the gap! Circulation 2020. [Ahead of Print]. 5. Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a Letter to Editor. Arch Acad Emerg Med 2020;8:e17. Letters to the Editor
{"title":"Increased Risk of Arrhythmia in COVID-19 Patients: Possible Roles of Both the Disease Pathophysiology and Adverse Drug Reactions.","authors":"Ali Rismanbaf","doi":"10.4103/jrpp.JRPP_20_63","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_63","url":null,"abstract":"References 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Discovery of a Novel Coronavirus Associated with the Recent Pneumonia Outbreak in Humans and its Potential Bat Origin. BioRxiv; 2020. 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9. 3. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60. 4. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: Mind the gap! Circulation 2020. [Ahead of Print]. 5. Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a Letter to Editor. Arch Acad Emerg Med 2020;8:e17. Letters to the Editor","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 3","pages":"165"},"PeriodicalIF":1.0,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/e5/JRPP-9-165.PMC7808179.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38789580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Effect of Oral Midazolam in Pain Relief of Patients Need Nasogastric Tube Insertion: A Clinical Trial Study. 口服药咪达唑仑缓解鼻胃管插入患者疼痛的效果:一项临床试验研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2020-10-08 eCollection Date: 2020-07-01 DOI: 10.4103/2319-9644.297561

[This corrects the article on p. 112 in vol. 9, PMID: 33102386.].

[这更正了第9卷第112页的文章,PMID: 33102386]。
{"title":"Erratum: Effect of Oral Midazolam in Pain Relief of Patients Need Nasogastric Tube Insertion: A Clinical Trial Study.","authors":"","doi":"10.4103/2319-9644.297561","DOIUrl":"https://doi.org/10.4103/2319-9644.297561","url":null,"abstract":"<p><p>[This corrects the article on p. 112 in vol. 9, PMID: 33102386.].</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 3","pages":"167"},"PeriodicalIF":1.0,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/f4/JRPP-9-167.PMC7808176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38855195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities. 己酮茶碱预防两性霉素b所致肾毒性和电解质异常。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2020-10-08 eCollection Date: 2020-07-01 DOI: 10.4103/jrpp.JRPP_20_98
Mahsa Panahi-Shokouh, Azadeh Moghaddas, Shirinsadat Badri, Saeedeh Jabalameli, Mahnaz Momenzadeh, Valiollah Mehrzad, Farzaneh Ashrafi

Objective: Amphotericin B is an antifungal agent used to treat serious fungal infections mainly in critically ill patients. Despite its adverse effects including renal toxicity and electrolyte imbalances, amphotericin B remains one of the best choices for antifungal treatment. Information from animal studies has provided a strong scientific basis for the use of pentoxifylline as lowering nephroprotective agent. The present study was designed to evaluate the efficacy of pentoxifylline in preventing renal toxicity and electrolytes imbalances induced by amphotericin B.

Methods: This study was conducted as a randomized controlled trial on 44 patients admitted to Sayyedoshohada Hospital, Isfahan, Iran, from October 2016 to August 2018. Patients were assigned to one of the two groups: Pentoxifylline, 400 mg twice a day, or matching placebo, from the 1st day of amphotericin B therapy till minimum of 7 days. All patients' information including lab data (serum and urine levels of Mg, Na, and K, serum creatinine level, blood urea nitrogen [BUN] and urinary creatinine excretion) were gathered at the time of drug initiation and during the study period. The results were analyzed by SPSS v. 20 software and Repeated measures test was used to assess the differences between groups.

Findings: This study did not show any significant differences between the two groups in terms of all the assessed variables, including serum and urinary levels of electrolytes, and creatinine, as well as the number of cases presented acute kidney injury during the study period.

Conclusion: Despite the positive effects of pentoxifylline in preventing renal complications in previous studies, this study could not show a definitive result in salt wasting or renal damage induced by amphotericin B. So, Designing robust studies with more included samples would be valuable.

目的:两性霉素B是一种主要用于治疗重症真菌感染的抗真菌药物。尽管其副作用包括肾毒性和电解质失衡,两性霉素B仍然是抗真菌治疗的最佳选择之一。来自动物研究的信息为己酮茶碱作为降肾保护剂的使用提供了强有力的科学依据。本研究旨在评价pentoxifylline对两性霉素b所致肾毒性和电解质失衡的预防作用。方法:本研究采用随机对照试验,选取2016年10月至2018年8月在伊朗伊斯法罕Sayyedoshohada医院住院的44例患者。从两性霉素B治疗的第一天开始,患者被分配到两组中的一组:己酮茶碱,400毫克,每天两次,或匹配的安慰剂,直到至少7天。收集所有患者在用药时和研究期间的实验室数据(血清和尿Mg、Na、K水平,血清肌酐水平,血尿素氮[BUN]和尿肌酐排泄量)。采用SPSS v. 20软件对结果进行分析,采用重复测量检验评价组间差异。研究结果:在所有评估变量方面,包括血清和尿液电解质水平、肌酐水平,以及研究期间出现急性肾损伤的病例数,本研究未显示两组之间有任何显著差异。结论:尽管己酮茶碱在既往研究中有预防肾脏并发症的积极作用,但本研究不能明确显示两性霉素b引起的盐消耗或肾脏损害,因此设计更多纳入样本的可靠研究是有价值的。
{"title":"Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities.","authors":"Mahsa Panahi-Shokouh,&nbsp;Azadeh Moghaddas,&nbsp;Shirinsadat Badri,&nbsp;Saeedeh Jabalameli,&nbsp;Mahnaz Momenzadeh,&nbsp;Valiollah Mehrzad,&nbsp;Farzaneh Ashrafi","doi":"10.4103/jrpp.JRPP_20_98","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_98","url":null,"abstract":"<p><strong>Objective: </strong>Amphotericin B is an antifungal agent used to treat serious fungal infections mainly in critically ill patients. Despite its adverse effects including renal toxicity and electrolyte imbalances, amphotericin B remains one of the best choices for antifungal treatment. Information from animal studies has provided a strong scientific basis for the use of pentoxifylline as lowering nephroprotective agent. The present study was designed to evaluate the efficacy of pentoxifylline in preventing renal toxicity and electrolytes imbalances induced by amphotericin B.</p><p><strong>Methods: </strong>This study was conducted as a randomized controlled trial on 44 patients admitted to Sayyedoshohada Hospital, Isfahan, Iran, from October 2016 to August 2018. Patients were assigned to one of the two groups: Pentoxifylline, 400 mg twice a day, or matching placebo, from the 1<sup>st</sup> day of amphotericin B therapy till minimum of 7 days. All patients' information including lab data (serum and urine levels of Mg, Na, and K, serum creatinine level, blood urea nitrogen [BUN] and urinary creatinine excretion) were gathered at the time of drug initiation and during the study period. The results were analyzed by SPSS v. 20 software and Repeated measures test was used to assess the differences between groups.</p><p><strong>Findings: </strong>This study did not show any significant differences between the two groups in terms of all the assessed variables, including serum and urinary levels of electrolytes, and creatinine, as well as the number of cases presented acute kidney injury during the study period.</p><p><strong>Conclusion: </strong>Despite the positive effects of pentoxifylline in preventing renal complications in previous studies, this study could not show a definitive result in salt wasting or renal damage induced by amphotericin B. So, Designing robust studies with more included samples would be valuable.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 3","pages":"135-139"},"PeriodicalIF":1.0,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/cc/JRPP-9-135.PMC7808184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38776452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1